Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection

Maxwell O. Akanbi, Kimberly Scarci, Babafemi Taiwo, Robert L. Murphy

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed-dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drugdrug interaction, preexisting antiretroviral drug resistance and comorbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. Areas covered: This article reviews N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials that have influenced treatment guidelines are discussed. Expert opinion: It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV coinfection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared with current N(t)RTIs.

Original languageEnglish (US)
Pages (from-to)65-79
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Reverse Transcriptase Inhibitors
Nucleosides
HIV Infections
Nucleotides
HIV
Pharmacology
Anti-Retroviral Agents
HIV-2
Expert Testimony
Coinfection
Drug Resistance
Clinical Trials

Keywords

  • Antiretroviral therapy
  • HIV
  • Nucleoside reverse transcriptase inhibitors
  • Nucleotide reverse transcriptase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. / Akanbi, Maxwell O.; Scarci, Kimberly; Taiwo, Babafemi; Murphy, Robert L.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 1, 01.01.2012, p. 65-79.

Research output: Contribution to journalReview article

Akanbi, Maxwell O. ; Scarci, Kimberly ; Taiwo, Babafemi ; Murphy, Robert L. / Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 1. pp. 65-79.
@article{34f9d381004541d4b9ce07288febfe52,
title = "Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection",
abstract = "Introduction: The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed-dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drugdrug interaction, preexisting antiretroviral drug resistance and comorbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. Areas covered: This article reviews N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials that have influenced treatment guidelines are discussed. Expert opinion: It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV coinfection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared with current N(t)RTIs.",
keywords = "Antiretroviral therapy, HIV, Nucleoside reverse transcriptase inhibitors, Nucleotide reverse transcriptase inhibitor",
author = "Akanbi, {Maxwell O.} and Kimberly Scarci and Babafemi Taiwo and Murphy, {Robert L.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1517/14656566.2012.642865",
language = "English (US)",
volume = "13",
pages = "65--79",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection

AU - Akanbi, Maxwell O.

AU - Scarci, Kimberly

AU - Taiwo, Babafemi

AU - Murphy, Robert L.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Introduction: The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed-dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drugdrug interaction, preexisting antiretroviral drug resistance and comorbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. Areas covered: This article reviews N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials that have influenced treatment guidelines are discussed. Expert opinion: It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV coinfection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared with current N(t)RTIs.

AB - Introduction: The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed-dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drugdrug interaction, preexisting antiretroviral drug resistance and comorbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. Areas covered: This article reviews N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials that have influenced treatment guidelines are discussed. Expert opinion: It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV coinfection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared with current N(t)RTIs.

KW - Antiretroviral therapy

KW - HIV

KW - Nucleoside reverse transcriptase inhibitors

KW - Nucleotide reverse transcriptase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=83455201429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455201429&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.642865

DO - 10.1517/14656566.2012.642865

M3 - Review article

C2 - 22149368

AN - SCOPUS:83455201429

VL - 13

SP - 65

EP - 79

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -